Incannex Healthcare Inc. (IXHL): Nasdaq/NYSE listing notice — Incannex Healthcare gets Nasdaq bid price compliance extension to April 20, 2026

Incannex Healthcare Inc.

Received second 180-day grace period from Nasdaq until April 20, 2026 to regain $1 minimum bid price.
Failed bid price requirement; transferred to Nasdaq Capital Market on July 10, 2025.
Must close at $1 or above for 10 consecutive business days during extension to comply.
Company intends to cure deficiency via reverse stock split if necessary.
Listing on Nasdaq Capital Market continues; no immediate delisting effect.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.82

Incannex Healthcare Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: late filing
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

April 20, 2026 (the “Second Grace Period”) to regain compliance with the Bid Price Requirement. According to the notification from Nasdaq, the Staff’s determination was based on (i) the Company meeting the continued listing requirement for market value of its publicly held shares and all other Nasdaq initial listing standards, with the exception of the Bid Price Requirement, and (ii) the Company’s written notice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. If at any time during this Second Grace Period

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Incannex Healthcare Inc. filing history →

Source: SEC EDGAR

accession 0001213900-25-100980

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.